Amgen Inc.

Thursday saw major U.S. indices closing on a positive note, with the Dow Jones Industrial Average climbing 0.85% to reach 38,225.66, while the S&P also showed gains, up 0.9% to 5,064.20. Additionally, the Nasdaq surged 1.5% to finish the day at 15,840.96. These are the top stocks that gained...

Amgen Inc. (NASDAQ: AMGN) delivered a solid earnings report after the market closed on August 3. Shareholders hope the results will be enough to reverse the fortunes of AMGN stock, down 12% in 2023.  But heading into earnings, analyst sentiment suggests that all the growth may already be...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Over the past decade, big pharma has largely stepped away from the research and development of psychiatric drugs. This came after what was...

The race for a novel coronavirus vaccine has lit a fuse under biotech and pharmaceutical companies. 2020 will surely be remembered as the year of COVID-19 and an unprecedented boom for these industries. During good times, pharma stocks are attractive because of their steady cash flow, high-profit...

Things are starting to heat up in the already hot pharmaceutical sector – especially as it relates to mergers and acquisitions. Only days after Onyx Pharmaceuticals (NASDAQ: ONXX) said it rejected an $8.7 billion buyout offer from Amgen (NASDAQ: AMGN), according to Reuters, the company has...

Onyx Pharmaceuticals (NASDAQ: ONXX), Friday, turned down an offer from Amgen (NASDAQ: AMGN) to acquire all of Onyx's outstanding shares for $120 per share in cash, according to The Wall Street Journal. While Onyx said the proposed offer from Amgen significantly undervalued Onyx, the company did...